英国两大**医学期刊Lancet和BMJ为他汀“互掐”:Lancet要求制裁BMJ,并谴责国际出版道德委员会不作为

2016-10-11 许菁 中国循环杂志

正在希拉里·克林顿和唐纳德·特朗普激烈 “互掐”时,英国两大顶级医学期刊《柳叶刀》(Lancet)和《英国医学杂志》(BMJ)也来凑热闹,为他汀的安全性“互掐”起来。 这场争论起始于2014年BMJ上发表的两篇批判他汀的文章。文章称,大约有20%服用这类药的人将可能损害肝脏和产生肾脏问题的数据。这两篇文章的研究在很大程度上是基于低质量的观察性数据。 哈佛大学的Rory Collins要

正在希拉里·克林顿和唐纳德·特朗普激烈 “互掐”时,英国两大顶级医学期刊《柳叶刀》(Lancet)和《英国医学杂志》(BMJ)也来凑热闹,为他汀的安全性“互掐”起来。

这场争论起始于2014年BMJ上发表的两篇批判他汀的文章。文章称,大约有20%服用这类药的人将可能损害肝脏和产生肾脏问题的数据。这两篇文章的研究在很大程度上是基于低质量的观察性数据。 哈佛大学的Rory Collins要求BMJ撤回该文章,还成立了专门调查小组进行了很长时间的审查,最终BMJ仅仅发了相关的更正声明,但并未撤销文章。 后来,牛津大学研究发现,对于他汀的争论已经影响了公众服用此类药物的比例,并导致他汀药处方的下降:对于采用他汀来进行一级预防的患者,停用他汀可能性的增加了11%,用于二级预防的患者停止他汀的可能性增加了12%。 上周,Lancet刊发了Rory Collins 教授撰写的长达30页的报告,他表示,人们低估了他汀类药物的临床应用价值,反而夸大了他汀的不良反应。 数据显示,如果1万人使用他汀5年,使胆固醇降低2 mmol/L,对于已有心血管病的患者,可以减少1***发生心血管事件;与此同时,他汀的不良反应仅仅是5人发生肌病,如果不停药的话,会有1人发生肌溶解。 Lancet杂志主编Richard Horton 针对这篇综述撰写了述评,支持Rory Collins 向国际出版道德委员会(COPE)提出申请,要求制裁BMJ,并谴责国际出版道德委员会拒绝调查资深科学家对这一关切问题的不作为。 针对Lancet杂志主编的言论,BMJ于上周四发布声明指出,Lancet杂志主编误解了国际出版道德委员会,并呈上国际出版道德委员会针对此次争论所作出的裁决。 国际出版道德委员会确实调查了此事,但并未认同Rory Collins及其支持者的观点,国际出版道德委员会认为那篇文章并不符合撤回的标准,而且发表这类文章并非不道德。 BMJ主编Fiona Godlee说,他已致信给英格兰首席医疗官Sally Davies,请求成立专门调查小组调查他汀的证据。 BMJ发布的声明中也清楚的表明,BMJ主编曾邀请Rory Collins针对这篇有争议的文章发表他的看法,但被拒绝了。 针对此次争论,BMJ同样发表了耶鲁大学Harlan Krumholz教授撰写的社论,Krumholz在总体上认同他汀的临床价值,但同时也针对相关临床试验的一些局限性提出了意见,并建议重新核查这些研究数据,只有这样才能进一步达成共识。 牛津大学资深咨询研究员Richard Lehman在BMJ的官方微博上针对他汀不良反应发表了看法,他说肌痛和疲劳这些不良反应是确实存在的,而且在那些应用他汀的患者中非常普遍且发生率不低,这一点是绝对不能忽视的,我们要搞清楚的是,现实中的这些问题为何与临床试验结果不一致呢? Richard Lehman说,他汀的这些不良反应确实让那些他汀的拥护者稍显“底气不足”,但是证明这类药物确实有效的临床研究数据有很多,目前争论的焦点在BMJ发表的那两篇短短的文章是否让公众对他汀有了质疑,事实上,Lancet更应该做的是让这些可靠的数据展现出来,这才是最有说服力的……..

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (17)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1848121, encodeId=cd7c1848121e6, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Sun Dec 04 13:14:00 CST 2016, time=2016-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=151394, encodeId=788a151394d9, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q3auHgzwzM5BsrBmMics21cibPpACY1aW8Ig0NzAiciasgcohylledUmBW553YwoDEcEdAzhiaXZoItyhD5r5o3G8Jg/132, createdBy=b2ee1972001, createdName=想想响响, createdTime=Wed Oct 26 22:22:06 CST 2016, time=2016-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1828642, encodeId=4fde182864215, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sun Nov 06 07:14:00 CST 2016, time=2016-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=148635, encodeId=27a9148635e6, content=可以学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4d81689617, createdName=Peteratanter, createdTime=Sat Oct 15 17:10:02 CST 2016, time=2016-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=147330, encodeId=c9b614e33071, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K3j7ibEWPiarwpqibEYqqX9yVibV5uebib0O7hQSOPmqGrb5FfyDbLsLawnz7ShAb5ibtiayWgI5ClMTh5v/0, createdBy=a47c1614293, createdName=童小孩, createdTime=Thu Oct 13 07:59:41 CST 2016, time=2016-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513906, encodeId=c43a1513906b0, content=<a href='/topic/show?id=45ca34140ec' target=_blank style='color:#2F92EE;'>#医学期刊#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34140, encryptionId=45ca34140ec, topicName=医学期刊)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=49a210597497, createdName=1249884fm90暂无昵称, createdTime=Thu Oct 13 04:14:00 CST 2016, time=2016-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=146734, encodeId=d1a8146e34f3, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K3j7ibEWPiarwpqibEYqqX9yVibV5uebib0O7hQSOPmqGrb5FfyDbLsLawnz7ShAb5ibtiayWgI5ClMTh5v/0, createdBy=a47c1614293, createdName=童小孩, createdTime=Wed Oct 12 12:55:36 CST 2016, time=2016-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=146211, encodeId=57bb14621165, content=他汀的封神还是要慎重, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9611710563, createdName=Oriharaizaya, createdTime=Tue Oct 11 23:51:14 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145394, encodeId=79f7145394cd, content=好文章,受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Tue Oct 11 20:18:13 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=144533, encodeId=ed84144533bf, content=是药就有不良反应,只是看不良反应是否在接受范围内, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39841962919, createdName=baoliliu, createdTime=Tue Oct 11 15:44:50 CST 2016, time=2016-10-11, status=1, ipAttribution=)]
    2016-12-04 仁心济世
  2. [GetPortalCommentsPageByObjectIdResponse(id=1848121, encodeId=cd7c1848121e6, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Sun Dec 04 13:14:00 CST 2016, time=2016-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=151394, encodeId=788a151394d9, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q3auHgzwzM5BsrBmMics21cibPpACY1aW8Ig0NzAiciasgcohylledUmBW553YwoDEcEdAzhiaXZoItyhD5r5o3G8Jg/132, createdBy=b2ee1972001, createdName=想想响响, createdTime=Wed Oct 26 22:22:06 CST 2016, time=2016-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1828642, encodeId=4fde182864215, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sun Nov 06 07:14:00 CST 2016, time=2016-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=148635, encodeId=27a9148635e6, content=可以学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4d81689617, createdName=Peteratanter, createdTime=Sat Oct 15 17:10:02 CST 2016, time=2016-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=147330, encodeId=c9b614e33071, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K3j7ibEWPiarwpqibEYqqX9yVibV5uebib0O7hQSOPmqGrb5FfyDbLsLawnz7ShAb5ibtiayWgI5ClMTh5v/0, createdBy=a47c1614293, createdName=童小孩, createdTime=Thu Oct 13 07:59:41 CST 2016, time=2016-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513906, encodeId=c43a1513906b0, content=<a href='/topic/show?id=45ca34140ec' target=_blank style='color:#2F92EE;'>#医学期刊#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34140, encryptionId=45ca34140ec, topicName=医学期刊)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=49a210597497, createdName=1249884fm90暂无昵称, createdTime=Thu Oct 13 04:14:00 CST 2016, time=2016-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=146734, encodeId=d1a8146e34f3, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K3j7ibEWPiarwpqibEYqqX9yVibV5uebib0O7hQSOPmqGrb5FfyDbLsLawnz7ShAb5ibtiayWgI5ClMTh5v/0, createdBy=a47c1614293, createdName=童小孩, createdTime=Wed Oct 12 12:55:36 CST 2016, time=2016-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=146211, encodeId=57bb14621165, content=他汀的封神还是要慎重, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9611710563, createdName=Oriharaizaya, createdTime=Tue Oct 11 23:51:14 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145394, encodeId=79f7145394cd, content=好文章,受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Tue Oct 11 20:18:13 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=144533, encodeId=ed84144533bf, content=是药就有不良反应,只是看不良反应是否在接受范围内, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39841962919, createdName=baoliliu, createdTime=Tue Oct 11 15:44:50 CST 2016, time=2016-10-11, status=1, ipAttribution=)]
    2016-10-26 想想响响

    值得学习

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1848121, encodeId=cd7c1848121e6, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Sun Dec 04 13:14:00 CST 2016, time=2016-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=151394, encodeId=788a151394d9, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q3auHgzwzM5BsrBmMics21cibPpACY1aW8Ig0NzAiciasgcohylledUmBW553YwoDEcEdAzhiaXZoItyhD5r5o3G8Jg/132, createdBy=b2ee1972001, createdName=想想响响, createdTime=Wed Oct 26 22:22:06 CST 2016, time=2016-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1828642, encodeId=4fde182864215, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sun Nov 06 07:14:00 CST 2016, time=2016-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=148635, encodeId=27a9148635e6, content=可以学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4d81689617, createdName=Peteratanter, createdTime=Sat Oct 15 17:10:02 CST 2016, time=2016-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=147330, encodeId=c9b614e33071, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K3j7ibEWPiarwpqibEYqqX9yVibV5uebib0O7hQSOPmqGrb5FfyDbLsLawnz7ShAb5ibtiayWgI5ClMTh5v/0, createdBy=a47c1614293, createdName=童小孩, createdTime=Thu Oct 13 07:59:41 CST 2016, time=2016-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513906, encodeId=c43a1513906b0, content=<a href='/topic/show?id=45ca34140ec' target=_blank style='color:#2F92EE;'>#医学期刊#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34140, encryptionId=45ca34140ec, topicName=医学期刊)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=49a210597497, createdName=1249884fm90暂无昵称, createdTime=Thu Oct 13 04:14:00 CST 2016, time=2016-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=146734, encodeId=d1a8146e34f3, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K3j7ibEWPiarwpqibEYqqX9yVibV5uebib0O7hQSOPmqGrb5FfyDbLsLawnz7ShAb5ibtiayWgI5ClMTh5v/0, createdBy=a47c1614293, createdName=童小孩, createdTime=Wed Oct 12 12:55:36 CST 2016, time=2016-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=146211, encodeId=57bb14621165, content=他汀的封神还是要慎重, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9611710563, createdName=Oriharaizaya, createdTime=Tue Oct 11 23:51:14 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145394, encodeId=79f7145394cd, content=好文章,受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Tue Oct 11 20:18:13 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=144533, encodeId=ed84144533bf, content=是药就有不良反应,只是看不良反应是否在接受范围内, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39841962919, createdName=baoliliu, createdTime=Tue Oct 11 15:44:50 CST 2016, time=2016-10-11, status=1, ipAttribution=)]
    2016-11-06 howi
  4. [GetPortalCommentsPageByObjectIdResponse(id=1848121, encodeId=cd7c1848121e6, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Sun Dec 04 13:14:00 CST 2016, time=2016-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=151394, encodeId=788a151394d9, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q3auHgzwzM5BsrBmMics21cibPpACY1aW8Ig0NzAiciasgcohylledUmBW553YwoDEcEdAzhiaXZoItyhD5r5o3G8Jg/132, createdBy=b2ee1972001, createdName=想想响响, createdTime=Wed Oct 26 22:22:06 CST 2016, time=2016-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1828642, encodeId=4fde182864215, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sun Nov 06 07:14:00 CST 2016, time=2016-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=148635, encodeId=27a9148635e6, content=可以学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4d81689617, createdName=Peteratanter, createdTime=Sat Oct 15 17:10:02 CST 2016, time=2016-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=147330, encodeId=c9b614e33071, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K3j7ibEWPiarwpqibEYqqX9yVibV5uebib0O7hQSOPmqGrb5FfyDbLsLawnz7ShAb5ibtiayWgI5ClMTh5v/0, createdBy=a47c1614293, createdName=童小孩, createdTime=Thu Oct 13 07:59:41 CST 2016, time=2016-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513906, encodeId=c43a1513906b0, content=<a href='/topic/show?id=45ca34140ec' target=_blank style='color:#2F92EE;'>#医学期刊#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34140, encryptionId=45ca34140ec, topicName=医学期刊)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=49a210597497, createdName=1249884fm90暂无昵称, createdTime=Thu Oct 13 04:14:00 CST 2016, time=2016-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=146734, encodeId=d1a8146e34f3, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K3j7ibEWPiarwpqibEYqqX9yVibV5uebib0O7hQSOPmqGrb5FfyDbLsLawnz7ShAb5ibtiayWgI5ClMTh5v/0, createdBy=a47c1614293, createdName=童小孩, createdTime=Wed Oct 12 12:55:36 CST 2016, time=2016-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=146211, encodeId=57bb14621165, content=他汀的封神还是要慎重, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9611710563, createdName=Oriharaizaya, createdTime=Tue Oct 11 23:51:14 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145394, encodeId=79f7145394cd, content=好文章,受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Tue Oct 11 20:18:13 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=144533, encodeId=ed84144533bf, content=是药就有不良反应,只是看不良反应是否在接受范围内, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39841962919, createdName=baoliliu, createdTime=Tue Oct 11 15:44:50 CST 2016, time=2016-10-11, status=1, ipAttribution=)]
    2016-10-15 Peteratanter

    可以学习一下

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1848121, encodeId=cd7c1848121e6, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Sun Dec 04 13:14:00 CST 2016, time=2016-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=151394, encodeId=788a151394d9, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q3auHgzwzM5BsrBmMics21cibPpACY1aW8Ig0NzAiciasgcohylledUmBW553YwoDEcEdAzhiaXZoItyhD5r5o3G8Jg/132, createdBy=b2ee1972001, createdName=想想响响, createdTime=Wed Oct 26 22:22:06 CST 2016, time=2016-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1828642, encodeId=4fde182864215, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sun Nov 06 07:14:00 CST 2016, time=2016-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=148635, encodeId=27a9148635e6, content=可以学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4d81689617, createdName=Peteratanter, createdTime=Sat Oct 15 17:10:02 CST 2016, time=2016-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=147330, encodeId=c9b614e33071, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K3j7ibEWPiarwpqibEYqqX9yVibV5uebib0O7hQSOPmqGrb5FfyDbLsLawnz7ShAb5ibtiayWgI5ClMTh5v/0, createdBy=a47c1614293, createdName=童小孩, createdTime=Thu Oct 13 07:59:41 CST 2016, time=2016-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513906, encodeId=c43a1513906b0, content=<a href='/topic/show?id=45ca34140ec' target=_blank style='color:#2F92EE;'>#医学期刊#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34140, encryptionId=45ca34140ec, topicName=医学期刊)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=49a210597497, createdName=1249884fm90暂无昵称, createdTime=Thu Oct 13 04:14:00 CST 2016, time=2016-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=146734, encodeId=d1a8146e34f3, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K3j7ibEWPiarwpqibEYqqX9yVibV5uebib0O7hQSOPmqGrb5FfyDbLsLawnz7ShAb5ibtiayWgI5ClMTh5v/0, createdBy=a47c1614293, createdName=童小孩, createdTime=Wed Oct 12 12:55:36 CST 2016, time=2016-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=146211, encodeId=57bb14621165, content=他汀的封神还是要慎重, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9611710563, createdName=Oriharaizaya, createdTime=Tue Oct 11 23:51:14 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145394, encodeId=79f7145394cd, content=好文章,受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Tue Oct 11 20:18:13 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=144533, encodeId=ed84144533bf, content=是药就有不良反应,只是看不良反应是否在接受范围内, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39841962919, createdName=baoliliu, createdTime=Tue Oct 11 15:44:50 CST 2016, time=2016-10-11, status=1, ipAttribution=)]
    2016-10-13 童小孩

    继续关注

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1848121, encodeId=cd7c1848121e6, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Sun Dec 04 13:14:00 CST 2016, time=2016-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=151394, encodeId=788a151394d9, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q3auHgzwzM5BsrBmMics21cibPpACY1aW8Ig0NzAiciasgcohylledUmBW553YwoDEcEdAzhiaXZoItyhD5r5o3G8Jg/132, createdBy=b2ee1972001, createdName=想想响响, createdTime=Wed Oct 26 22:22:06 CST 2016, time=2016-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1828642, encodeId=4fde182864215, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sun Nov 06 07:14:00 CST 2016, time=2016-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=148635, encodeId=27a9148635e6, content=可以学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4d81689617, createdName=Peteratanter, createdTime=Sat Oct 15 17:10:02 CST 2016, time=2016-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=147330, encodeId=c9b614e33071, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K3j7ibEWPiarwpqibEYqqX9yVibV5uebib0O7hQSOPmqGrb5FfyDbLsLawnz7ShAb5ibtiayWgI5ClMTh5v/0, createdBy=a47c1614293, createdName=童小孩, createdTime=Thu Oct 13 07:59:41 CST 2016, time=2016-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513906, encodeId=c43a1513906b0, content=<a href='/topic/show?id=45ca34140ec' target=_blank style='color:#2F92EE;'>#医学期刊#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34140, encryptionId=45ca34140ec, topicName=医学期刊)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=49a210597497, createdName=1249884fm90暂无昵称, createdTime=Thu Oct 13 04:14:00 CST 2016, time=2016-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=146734, encodeId=d1a8146e34f3, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K3j7ibEWPiarwpqibEYqqX9yVibV5uebib0O7hQSOPmqGrb5FfyDbLsLawnz7ShAb5ibtiayWgI5ClMTh5v/0, createdBy=a47c1614293, createdName=童小孩, createdTime=Wed Oct 12 12:55:36 CST 2016, time=2016-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=146211, encodeId=57bb14621165, content=他汀的封神还是要慎重, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9611710563, createdName=Oriharaizaya, createdTime=Tue Oct 11 23:51:14 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145394, encodeId=79f7145394cd, content=好文章,受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Tue Oct 11 20:18:13 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=144533, encodeId=ed84144533bf, content=是药就有不良反应,只是看不良反应是否在接受范围内, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39841962919, createdName=baoliliu, createdTime=Tue Oct 11 15:44:50 CST 2016, time=2016-10-11, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1848121, encodeId=cd7c1848121e6, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Sun Dec 04 13:14:00 CST 2016, time=2016-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=151394, encodeId=788a151394d9, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q3auHgzwzM5BsrBmMics21cibPpACY1aW8Ig0NzAiciasgcohylledUmBW553YwoDEcEdAzhiaXZoItyhD5r5o3G8Jg/132, createdBy=b2ee1972001, createdName=想想响响, createdTime=Wed Oct 26 22:22:06 CST 2016, time=2016-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1828642, encodeId=4fde182864215, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sun Nov 06 07:14:00 CST 2016, time=2016-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=148635, encodeId=27a9148635e6, content=可以学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4d81689617, createdName=Peteratanter, createdTime=Sat Oct 15 17:10:02 CST 2016, time=2016-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=147330, encodeId=c9b614e33071, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K3j7ibEWPiarwpqibEYqqX9yVibV5uebib0O7hQSOPmqGrb5FfyDbLsLawnz7ShAb5ibtiayWgI5ClMTh5v/0, createdBy=a47c1614293, createdName=童小孩, createdTime=Thu Oct 13 07:59:41 CST 2016, time=2016-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513906, encodeId=c43a1513906b0, content=<a href='/topic/show?id=45ca34140ec' target=_blank style='color:#2F92EE;'>#医学期刊#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34140, encryptionId=45ca34140ec, topicName=医学期刊)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=49a210597497, createdName=1249884fm90暂无昵称, createdTime=Thu Oct 13 04:14:00 CST 2016, time=2016-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=146734, encodeId=d1a8146e34f3, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K3j7ibEWPiarwpqibEYqqX9yVibV5uebib0O7hQSOPmqGrb5FfyDbLsLawnz7ShAb5ibtiayWgI5ClMTh5v/0, createdBy=a47c1614293, createdName=童小孩, createdTime=Wed Oct 12 12:55:36 CST 2016, time=2016-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=146211, encodeId=57bb14621165, content=他汀的封神还是要慎重, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9611710563, createdName=Oriharaizaya, createdTime=Tue Oct 11 23:51:14 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145394, encodeId=79f7145394cd, content=好文章,受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Tue Oct 11 20:18:13 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=144533, encodeId=ed84144533bf, content=是药就有不良反应,只是看不良反应是否在接受范围内, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39841962919, createdName=baoliliu, createdTime=Tue Oct 11 15:44:50 CST 2016, time=2016-10-11, status=1, ipAttribution=)]
    2016-10-12 童小孩

    继续关注

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1848121, encodeId=cd7c1848121e6, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Sun Dec 04 13:14:00 CST 2016, time=2016-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=151394, encodeId=788a151394d9, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q3auHgzwzM5BsrBmMics21cibPpACY1aW8Ig0NzAiciasgcohylledUmBW553YwoDEcEdAzhiaXZoItyhD5r5o3G8Jg/132, createdBy=b2ee1972001, createdName=想想响响, createdTime=Wed Oct 26 22:22:06 CST 2016, time=2016-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1828642, encodeId=4fde182864215, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sun Nov 06 07:14:00 CST 2016, time=2016-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=148635, encodeId=27a9148635e6, content=可以学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4d81689617, createdName=Peteratanter, createdTime=Sat Oct 15 17:10:02 CST 2016, time=2016-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=147330, encodeId=c9b614e33071, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K3j7ibEWPiarwpqibEYqqX9yVibV5uebib0O7hQSOPmqGrb5FfyDbLsLawnz7ShAb5ibtiayWgI5ClMTh5v/0, createdBy=a47c1614293, createdName=童小孩, createdTime=Thu Oct 13 07:59:41 CST 2016, time=2016-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513906, encodeId=c43a1513906b0, content=<a href='/topic/show?id=45ca34140ec' target=_blank style='color:#2F92EE;'>#医学期刊#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34140, encryptionId=45ca34140ec, topicName=医学期刊)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=49a210597497, createdName=1249884fm90暂无昵称, createdTime=Thu Oct 13 04:14:00 CST 2016, time=2016-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=146734, encodeId=d1a8146e34f3, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K3j7ibEWPiarwpqibEYqqX9yVibV5uebib0O7hQSOPmqGrb5FfyDbLsLawnz7ShAb5ibtiayWgI5ClMTh5v/0, createdBy=a47c1614293, createdName=童小孩, createdTime=Wed Oct 12 12:55:36 CST 2016, time=2016-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=146211, encodeId=57bb14621165, content=他汀的封神还是要慎重, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9611710563, createdName=Oriharaizaya, createdTime=Tue Oct 11 23:51:14 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145394, encodeId=79f7145394cd, content=好文章,受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Tue Oct 11 20:18:13 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=144533, encodeId=ed84144533bf, content=是药就有不良反应,只是看不良反应是否在接受范围内, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39841962919, createdName=baoliliu, createdTime=Tue Oct 11 15:44:50 CST 2016, time=2016-10-11, status=1, ipAttribution=)]
    2016-10-11 Oriharaizaya

    他汀的封神还是要慎重

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1848121, encodeId=cd7c1848121e6, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Sun Dec 04 13:14:00 CST 2016, time=2016-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=151394, encodeId=788a151394d9, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q3auHgzwzM5BsrBmMics21cibPpACY1aW8Ig0NzAiciasgcohylledUmBW553YwoDEcEdAzhiaXZoItyhD5r5o3G8Jg/132, createdBy=b2ee1972001, createdName=想想响响, createdTime=Wed Oct 26 22:22:06 CST 2016, time=2016-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1828642, encodeId=4fde182864215, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sun Nov 06 07:14:00 CST 2016, time=2016-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=148635, encodeId=27a9148635e6, content=可以学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4d81689617, createdName=Peteratanter, createdTime=Sat Oct 15 17:10:02 CST 2016, time=2016-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=147330, encodeId=c9b614e33071, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K3j7ibEWPiarwpqibEYqqX9yVibV5uebib0O7hQSOPmqGrb5FfyDbLsLawnz7ShAb5ibtiayWgI5ClMTh5v/0, createdBy=a47c1614293, createdName=童小孩, createdTime=Thu Oct 13 07:59:41 CST 2016, time=2016-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513906, encodeId=c43a1513906b0, content=<a href='/topic/show?id=45ca34140ec' target=_blank style='color:#2F92EE;'>#医学期刊#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34140, encryptionId=45ca34140ec, topicName=医学期刊)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=49a210597497, createdName=1249884fm90暂无昵称, createdTime=Thu Oct 13 04:14:00 CST 2016, time=2016-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=146734, encodeId=d1a8146e34f3, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K3j7ibEWPiarwpqibEYqqX9yVibV5uebib0O7hQSOPmqGrb5FfyDbLsLawnz7ShAb5ibtiayWgI5ClMTh5v/0, createdBy=a47c1614293, createdName=童小孩, createdTime=Wed Oct 12 12:55:36 CST 2016, time=2016-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=146211, encodeId=57bb14621165, content=他汀的封神还是要慎重, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9611710563, createdName=Oriharaizaya, createdTime=Tue Oct 11 23:51:14 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145394, encodeId=79f7145394cd, content=好文章,受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Tue Oct 11 20:18:13 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=144533, encodeId=ed84144533bf, content=是药就有不良反应,只是看不良反应是否在接受范围内, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39841962919, createdName=baoliliu, createdTime=Tue Oct 11 15:44:50 CST 2016, time=2016-10-11, status=1, ipAttribution=)]
    2016-10-11 1e10c84am36(暂无匿称)

    好文章,受益

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1848121, encodeId=cd7c1848121e6, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Sun Dec 04 13:14:00 CST 2016, time=2016-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=151394, encodeId=788a151394d9, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q3auHgzwzM5BsrBmMics21cibPpACY1aW8Ig0NzAiciasgcohylledUmBW553YwoDEcEdAzhiaXZoItyhD5r5o3G8Jg/132, createdBy=b2ee1972001, createdName=想想响响, createdTime=Wed Oct 26 22:22:06 CST 2016, time=2016-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1828642, encodeId=4fde182864215, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sun Nov 06 07:14:00 CST 2016, time=2016-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=148635, encodeId=27a9148635e6, content=可以学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4d81689617, createdName=Peteratanter, createdTime=Sat Oct 15 17:10:02 CST 2016, time=2016-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=147330, encodeId=c9b614e33071, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K3j7ibEWPiarwpqibEYqqX9yVibV5uebib0O7hQSOPmqGrb5FfyDbLsLawnz7ShAb5ibtiayWgI5ClMTh5v/0, createdBy=a47c1614293, createdName=童小孩, createdTime=Thu Oct 13 07:59:41 CST 2016, time=2016-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513906, encodeId=c43a1513906b0, content=<a href='/topic/show?id=45ca34140ec' target=_blank style='color:#2F92EE;'>#医学期刊#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34140, encryptionId=45ca34140ec, topicName=医学期刊)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=49a210597497, createdName=1249884fm90暂无昵称, createdTime=Thu Oct 13 04:14:00 CST 2016, time=2016-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=146734, encodeId=d1a8146e34f3, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K3j7ibEWPiarwpqibEYqqX9yVibV5uebib0O7hQSOPmqGrb5FfyDbLsLawnz7ShAb5ibtiayWgI5ClMTh5v/0, createdBy=a47c1614293, createdName=童小孩, createdTime=Wed Oct 12 12:55:36 CST 2016, time=2016-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=146211, encodeId=57bb14621165, content=他汀的封神还是要慎重, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9611710563, createdName=Oriharaizaya, createdTime=Tue Oct 11 23:51:14 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145394, encodeId=79f7145394cd, content=好文章,受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Tue Oct 11 20:18:13 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=144533, encodeId=ed84144533bf, content=是药就有不良反应,只是看不良反应是否在接受范围内, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39841962919, createdName=baoliliu, createdTime=Tue Oct 11 15:44:50 CST 2016, time=2016-10-11, status=1, ipAttribution=)]
    2016-10-11 baoliliu

    是药就有不良反应,只是看不良反应是否在接受范围内

    0

相关资讯

JAHA:汀类药物对免疫系统的辅助作用!

他汀类药物预防心血管疾病的方式比以往认为的还要多。在一项研究中,来自卡罗林斯卡研究所的研究人员显示了他汀类药物的免疫效果,并提出了一个关于为什么他汀类药物能有效预防心脏病发作的新假说。这项研究发表在《美国心脏病协会杂志》上。 动脉粥样硬化可导致一系列严重的医学病症,如心脏发作、中风和间歇性跛行。这些心血管疾病及其他心血管疾病在世界各地都在增加。在西方,它们是主要的死亡原因。Johan Fro

防治冠心病、心梗的三类“神药”

常有各种广告推销治疗冠心病的“神药”,实际上真正的“神药”只有三类。只要在医生指导下长期合理的坚持服用这三类药物,就能够大幅度降低冠心病、心梗以及其他严重心血管事件的发生率。他汀他汀类药物(如阿托伐他汀、瑞舒伐他汀、辛伐他汀、氟伐他汀、匹伐他汀等)可以减少体内胆固醇的合成,降低血液中胆固醇水平,减少生成动脉粥样硬化斑块的“原料”,进而延缓斑块的增长,甚至使斑块变小,对冠心病起到有效的治疗作用。另外

Lancet Diabetes Endocrinol:使用他汀降低LDL-C,有益于慢性肾病

背景:对轻、中度慢性肾脏病患者,使用他汀类药物可有效预防冠心病和卒中风险;但是对于更严重的慢性肾脏病患者,比如透析患者,他汀类药物的效果又怎样?方法:对28项试验(n = 183 419)进行荟萃分析,研究他汀类药物为基础的治疗对大血管事件(冠状动脉事件[非致死性心肌梗死或冠心病死亡],卒中或冠状动脉血运重建)和病因特异性死亡率的影响。在基线时评估参与者的肾小球滤过率(eGFR)。结果:总的来说,

综述:他汀致新发糖尿病发病风险研究进展

美国糖尿病学会(ADA)在Diabetes Care发表了《2015年ADA糖尿病医学诊疗标准》[1],强调40岁以上糖尿病患者均应常规接受他汀治疗;40~75岁糖尿病患者应接受中等或高等强度的他汀治疗;此外,对所有伴心血管疾病的糖尿病患者以及存在任一心血管疾病风险因素的40~75岁患者,均应接受高强度他汀治疗。新版ADA指南一个明显变化是,对糖尿病患者是否应用他汀治疗及用药强度,应根据患者的

葛均波 孔灵芝 陈韵岱 孟宪励——膳食胆固醇究竟要不要控制?

目前从学术界到广大民众普遍关心一个热点话题:膳食胆固醇的摄入究竟要不要进行限制?这个问题正如哈姆雷特的那句“To be or not to be, that is the question.”不同的对象、不同的环境、不同的程度,自然会带来不同的结局。因此从这个意义而言,邀请权威专家讨论正是为了明确其界限,让科学的认知引导广大民众,及时传递对胆固醇的正确认识。问:胆固醇是导致动脉粥样硬化性心脏病

冠脉搭桥术后他汀和阿司匹林长期服用率需进一步提高

冠脉搭桥(CABG)是缺血性心脏病的有效治疗手段,但由于移植血管狭窄和阻塞发生率高,冠脉搭桥长期获益受到一定程度的限制。大量研究证实冠脉搭桥术后服用他汀类药物和阿司匹林可获益,近期美国心脏协会发布的 CABG 术后二级预防科学声明也将长期服用他汀和阿司匹林作为 Ia 类推荐。但是,针对他汀和阿司匹林长期服用情况的研究数据比较匮乏,为此,来自美国宾夕法尼亚州 Thomas Jefferson 大学附